TABLE 4.
Reviewer Agreement for Primary Pathophysiological Processes and Therapeutic Advances (N = 41)
| Standard Review/Independent Review | Agreement, n/N (%) | κ (95% CI) | ||||
|---|---|---|---|---|---|---|
| Yes/Yes | No/No | Yes/No | No/Yes | |||
| Pathophysiological processes | ||||||
| Impaired substrate delivery | 14 | 19 | 4 | 4 | 33/41 (80.5) | 0.60 (0.36 to 0.85) |
| Coagulation dysfunction | 4 | 33 | 2 | 2 | 37/41 (90.2) | 0.61 (0.26 to 0.96) |
| Inflammation | 11 | 25 | 5 | 0 | 36/41 (87.8) | 0.73 (0.51 to 0.94) |
| Immune dysfunction | 4 | 33 | 3 | 1 | 37/41 (90.2) | 0.61 (0.27 to 0.95) |
| Toxicities | 5 | 33 | 1 | 2 | 38/41 (92.7) | 0.73 (0.43 to 1.00) |
| Tissue injury (direct) | 4 | 33 | 3 | 1 | 37/41 (90.2) | 0.61 (0.27 to 0.95) |
| Malnutrition | 3 | 34 | 1 | 3 | 37/41 (90.2) | 0.55 (0.16 to 0.94) |
| Electrical signaling dysfunction | 9 | 28 | 3 | 1 | 37/41 (90.2) | 0.75 (0.52 to 0.98) |
| Abnormal growth or abnormal cell cycle | 2 | 31 | 5 | 3 | 33/41 (80.5) | 0.22 (−0.16 to 0.60) |
| Capillary or vascular dysfunction | 1 | 36 | 1 | 3 | 37/41 (90.2) | 0.29 (−0.21 to 0.79) |
| Mitochondrial dysfunction | 1 | 40 | 0 | 0 | 41/41 (100.0) | 1.00 (1.00 to 1.00) |
| Therapeutic needs | ||||||
| Mechanical respiratory support | 4 | 29 | 7 | 1 | 33/41 (80.5) | 0.40 (0.08 to 0.72) |
| Inhaled respiratory treatments | 0 | 39 | 1 | 1 | 39/41 (95.1) | −0.03 (−0.06 to 0.01) |
| Renal replacement therapy and plasmapheresis | 0 | 40 | 0 | 1 | 40/41 (97.6) | — |
| Extracorporeal support and artificial organs | 6 | 32 | 2 | 1 | 38/41 (92.7) | 0.76 (0.49 to 1.00) |
| Organ transplant | 3 | 27 | 3 | 8 | 30/41 (73.2) | 0.20 (−0.12 to 0.53) |
| Blood and blood products | 0 | 38 | 1 | 2 | 38/41 (92.7) | −0.03 (−0.08 to 0.01) |
| Drugs | 20 | 14 | 5 | 2 | 34/41 (82.9) | 0.65 (0.42 to 0.88) |
| Drug delivery | 0 | 41 | 0 | 0 | 41/41 (100.0) | — |
| Immune and inflammatory modulation | 6 | 30 | 4 | 1 | 36/41 (87.8) | 0.63 (0.34 to 0.92) |
| Nutritional support | 0 | 35 | 4 | 2 | 35/41 (85.4) | −0.07 (−0.14 to −0.00) |
| Therapeutic devices | 1 | 34 | 5 | 1 | 35/41 (85.4) | 0.19 (−0.20 to 0.59) |
| Monitoring devices | 0 | 37 | 1 | 3 | 37/41 (90.2) | −0.04 (−0.10 to 0.02) |
| Cellular regeneration | 5 | 23 | 9 | 4 | 28/41 (68.3) | 0.23 (−0.08 to 0.53) |
| Suspended animation | 0 | 41 | 0 | 0 | 41/41 (100.0) | — |
| Mitochondrial support | 1 | 40 | 0 | 0 | 41/41 (100.0) | 1.00 (1.00 to 1.00) |
A total of 41 cases underwent duplicate reviews at 2 sites. Agreement is indicated by “yes/yes” or “no/no” by the 2 reviewers. Disagreement is indicated by “yes/no” or “no/yes.” —, not applicable.